Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results

Core Insights - Collegium Pharmaceutical, Inc. reported record quarterly and full-year net revenue of $181.9 million and$631.4 million respectively for the year ended December 31, 2024, marking an 11% increase year-over-year [1][10] - The company achieved a quarterly GAAP net income of $12.5 million and a full-year GAAP net income of$69.2 million, with adjusted EBITDA reaching $107.7 million for the quarter and$401.2 million for the year [1][10] - Collegium ended 2024 with cash, cash equivalents, and marketable securities totaling $162.8 million and repurchased$60 million in shares during the year [1][10] Financial Performance - For the quarter ended December 31, 2024, product revenues, net were $181.9 million, a 22$149.7 million in the same quarter of 2023 [10] - GAAP operating expenses for the quarter were $60.2 million, an 83$32.9 million in the prior year [10] - Adjusted operating expenses for the quarter were $51.1 million, up 97$25.9 million year-over-year [10] Business Highlights - The company grew total revenue by 11% and adjusted EBITDA by 9% in 2024, while also completing an acquisition and executing $60 million in share repurchases [3][5] - Jornay PM prescriptions grew by 29$135 million in 2025 [5][10] - Belbuca total prescriptions increased by 5.6% year-over-year, with net revenue reaching a record $55.2 million for the quarter, up 12$735 million and $750 million, and adjusted EBITDA between$435 million and $450 million [5][10] - Collegium aims to maximize its pain portfolio and strategically deploy capital to create long-term value for shareholders [3][5] - The appointment of Nancy S. Lurker to the Board of Directors is expected to enhance the company's strategic direction [5]